Last reviewed · How we verify
Ad5-gag
At a glance
| Generic name | Ad5-gag |
|---|---|
| Sponsor | Centers for Disease Control and Prevention, China |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients (PHASE2)
- Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine (PHASE1)
- Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) (PHASE2)
- Investigation of V520 in a HIV Vaccine Dose Refinement Study (V520-027)(TERMINATED) (PHASE2)
- A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad5-gag CI brief — competitive landscape report
- Ad5-gag updates RSS · CI watch RSS
- Centers for Disease Control and Prevention, China portfolio CI